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Background:  Noroviruses  (NoVs)  are  a common  cause  of  acute  gastroenteritis  (AGE)  and  until  now,  little
is  known  about  its ability  to spread  outside  the gut.
Objectives: We  aim  to investigate  the  role of  NoVs  causing  viremia  in children  hospitalized  for  AGE,  as
well  as to  correlate  the  presence  of NoVs  RNA in serum  with clinical  severity  and  stool  viral  load.
Study  design:  Paired  stool  and  serum  samples  were  collected  from  85  pediatric  patients  under  6 years
hospitalized  for AGE  from  March  to  September  2012  in  Belém,  Brazil.  Enzyme-linked  immunosorbent
assay  (EIA)  and  reverse  transcription  quantitative  PCR  (RT-qPCR)  were  used  to detect  and  quantify  NoVs,
respectively.  Phylogenetic  analysis  of  the  partial  ORF2  region  was  used  to genotype  the  strains  detected.
Results:  NoVs  were  detected  in  34.1%  (29/85)  of  stool  samples.  By  qRT-PCR,  we found  a high  rate  of
NoVs’  RNA  in  serum  samples  (34.5%)  among  NoVs-positive  AGE cases,  and  was  associated  with  a longer
11 11hospitalization  (6.5  vs. 4.0  days;  p = 0.006),  as  well  as  with a higher  stool  viral  load  (3.9  × 10 vs. 1.1  × 10
GC/g;  p  = 0.0472).  NoVs  strains  were  classiﬁed  as  GII.4  (90%  of genotyped  strains)  and  GII.7 (10%).  The  same
genotype  was  found  in  paired  stool  and  serum  samples.
Conclusion:  Detection  and  molecular  characterization  of  NoVs  GII  in  paired  stool  and serum  samples
suggest  that  the dissemination  of  NoVs  to  the  blood  stream  is  not  uncommon,  but the role  of viruses
spread  outside  the gut and  the  relationship  with  disease  severity  need  to  be  further  addressed.
© 2013 Elsevier B.V. All rights reserved.. Background
Noroviruses (NoVs), members of the Caliciviridae family, are
mall, positive-polarity RNA viruses and were recently recognized
s the second most common cause of severe childhood gastroen-
eritis [1–3]. Worldwide, NoVs are responsible for almost 50%
f acute gastroenteritis (AGE) outbreaks and more than 90% of
he non-bacterial AGE, being considered the major pathogens
n outbreaks [1,4]. NoVs usually causes diarrhea and vomiting,
nd a number of other clinical manifestations are also observed:
ausea, abdominal cramps, fever, headache, chills, and myalgias
5,6]. Although NoVs-infection usually causes a short-term and
Abbreviations: NoVs, noroviruses; AGE, acute gastroenteritis; EIA, enzyme-
inked immunosorbent assay; RT-qPCR, reverse transcription quantitative PCR; nt,
ucleotide.
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ttp://dx.doi.org/10.1016/j.jcv.2013.06.043self-limiting disease, hospitalization is required when severe AGE
affects the elderly [7] and immunocompromised patients [8]. Par-
ticularly in developing countries, where a high childhood mortality
due to diarrhea is reported, NoVs have been estimated to cause up
to 200,000 deaths each year in children less than 5 years old [9].
Despite a high genetic diversity, at least 25 human genotypes, the
genogroup II, genotype 4 NoVs (GII.4) are responsible for the vast
majority of AGE outbreaks caused by NoVs reported worldwide
[1,5,6].
Particularly in the post-rotavirus vaccine era, NoVs have cap-
tured increasing attention as a major cause of AGE outbreaks and
hospitalizations in children less than 5 years old [10]. In addition to
the classic symptoms of AGE (watery diarrhea, vomiting, abdom-
inal pain, and fever), NoVs infection has been associated, though
to a lesser extent, with atypical clinical conditions such as seizures
[11,12], encephalopathy [13], and necrotizing enterocolitis [14,15].
It is unknown whether a relationship exists between these atypical
symptoms and NoVs dissemination to outside the digestive tract,
and worldwide, few studies have detected NoVs in blood samples
[12,13,16,17].
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respectively. GII.4 was the most prevalent genotype detected
(18/20–90%). Two samples were classiﬁed as genotype GII.7.2 T.M. Fumian et al. / Journal of
. Objectives
In the present study, we aimed to investigate the presence of
oVs in stool and serum samples of children admitted to hospital
ith symptoms of AGE. We  tested paired (stool/serum) samples to
earch for NoVs using an immune assay and molecular methods.
ata from pediatric patients were recorded to evaluate a possible
ssociation between NoVs RNA in serum, stool viral load, and AGE
linical features.
. Study design
.1. Clinical samples collection
During seven months of a pediatric hospital-based surveillance
tudy (March to September 2012), paired stool and serum samples
ere collected from children admitted in a pediatric clinic, located
n Belém city, Pará state, northern Brazil. Children less than 6 years
ospitalized for AGE (three or more liquid or semi-liquid evacua-
ions in a 24 h period) were included in the study. Clinical samples
ollected after 48 h of admission and children presenting with per-
istent diarrhea (>14 days) were excluded. Serum and stool samples
ere stored at −20 ◦C until RNA extraction.
This study, designed with the primary objective of assessing
otavirus viremia, was performed in accordance to the ethical
tandards of the Declaration of Helsinki and ethical approvals
ere obtained from an independent Ethics Committee on Human
esearch of Evandro Chagas Institute, Brazilian Ministry of Health
IEC-CEPH, protocol No. 0039/2011). For all samples’ collection, a
ritten informed consent was obtained from the patient’s parents
r legal guardians.
.2. Norovirus detection
Stool samples were initially tested for the presence of NoV
ntigen using the RIDASCREEN® Norovirus 3rd Generation (R-
iopharm AG, Germany) enzyme immunoassay (EIA) kit according
o the manufacturer’s instructions. EIA positive stool and all serum
amples were subjected to the reverse-transcriptase quantitative
CR (qRT-PCR) for NoV detection and quantiﬁcation. Prior to reac-
ion, RNA was puriﬁed from 140 l of a 10% stool suspension
r serum samples using the QIAamp Viral RNATM extraction kit
QIAGEN, CA, USA), and immediately stored at −70 ◦C prior NoV
etection/quantiﬁcation.
Ampliﬁcation, data acquisition and analysis were performed on
n ABI PRISM model 7500 Sequence Detection System (Applied
iosystems, Foster City, CA, USA), using primers and probe designed
y Kageyama et al. [18] and SuperScriptTM III Platinum® One-Step
uantitative RT-PCR System (Invitrogen, CA, USA). A 10-fold serial
ilution of a plasmid containing the ORF1/2 junction of NoVs GII
as used to generate a standard curve for viruses’ quantiﬁcation.
orty cycles were used in the reaction and the samples signals
hat crossed the threshold line, presenting a characteristic sigmoid
urve, were regarded as positive.
For all molecular procedures, separate rooms were used among
he different steps of viruses’ detection. To avoid cross contam-
nation, RNA puriﬁcation from stool and serum samples were
erformed separately. Samples were analyzed in duplicate; Pos-
tive clinical sample, DNase/RNase-free water and a no template
ontrol (NTC) were used as positive and negative controls in all
rocedures..3. Molecular characterization and phylogenetic analysis
For NoVs GII genetic characterization and phylogenetic anal-
sis, PCR (primers Mon431/432 [19] and G2SKR [20]) and semial Virology 58 (2013) 31– 35
nested-PCR (primers COG2F [18] and G2SKR [20]) were per-
formed targeting the 5′-end ORF2 region. Amplicons were puriﬁed
and sequenced using an ABI Prism BigDye Terminator Cycle
Sequencing Ready Reaction Kit® and the ABI Prism 3130xl DNA
Sequencer (Applied Biosystems, Foster City, CA, USA). Follow-
ing the chromatograms analyses, consensual sequences were
obtained using BioEdit [21]. A phylogenetic dendrogram was con-
structed by the neighbour-joining method using a matrix of genetic
distances established under the Kimura-two parameter model
using MEGA 5.05 [22]. NoV GII strains isolated from stool and
serum samples were classiﬁed according to the genotyping tool
[23] available on line and the sequences for 22 strains were
deposited in the GenBank under accession numbers KC165031 to
KC165052.
3.4. Statistical analysis
Statistical analyses were performed using GraphPad Prism®
software version 5. As appropriate, Mann–Whitney U test or Chi-
square was  used to assess signiﬁcant difference between features
recorded from children presenting AGE with and without NoVs RNA
detection in serum. A p value inferior to 0.05 was considered to be
statistically signiﬁcant.
4. Results
4.1. Noroviruses detection
During this surveillance study, paired stool and serum sam-
ples were obtained from 85 children hospitalized for AGE. NoVs
were detected in 34.1% (29/85) and 11.8% (10/85) of the stool and
serum samples collected, respectively. Among the NoVs positive
cases, NoVs RNA in serum was  demonstrated in 34.5% (10/29) of
the cases, suggesting viremia. Table 1 shows the clinical features
of AGE and NoVs viral load in the stool samples from hospital-
ized children classiﬁed within two groups: NoVs AGE  with and
without RNA detection in blood. The duration of diarrhea was
established from the onset of the clinical symptoms up to the
interview with parents/legal guardians, in general at the ﬁrst
day of hospitalization. Co-infection involving NoVs and group A
rotavirus (RVA) (data not shown) was  observed in six AGE cases
and were excluded from the analyses. All the six co-infection
were detected within the group without NoVs RNA detection in
serum.
The length of hospital stay (6.5 vs. 4.0 days; p = 0.006), and viral
load quantiﬁed from the stool samples [3.9 × 1011 vs. 1.1 × 1011
genome copies per gram (GC/g); p = 0.0472] showed statistically
signiﬁcant difference when comparing patients with and without
NoVs RNA in serum. We  observed a lower level of NoVs GC among
the group without viremia, represented by the Ct value (Fig. 1). For
serum samples, NoVs was  detected in a low level of GC  per ml,
ranging from 2.1 × 103 to 2 × 105 (mean of 4.9 × 104).
4.2. Norovirus characterization
NoVs was  genotyped by sequencing the partial 5′-end of ORF-
2 region [320 nucleotide (nt) in length]. A total of 69% (20/29)
and 20% (2/10) of the stool and serum samples were sequenced,Among the GII.4 strains detected, 100% were classiﬁed as 2010 vari-
ant (Fig. 2). The two  NoVs strains sequenced from serum samples
were classiﬁed as GII.4 and nt sequences matched 100%, comparing
paired stool and serum sample each other.
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Table  1
Clinical features and stool viral load in NoVs-infected children hospitalized with AGE with and without NoVs RNA in sera.
Clinical feature NoVs AGE with NoVs RNA in serum NoVs AGE without NoVs RNA in serum Statistical analysis
(n  = 10) (n = 13)e p
Number of evacuations per daya 4 (3–8) 5 (3–8) 0.457
Duration of diarrhea, daysa,d 3.5 (1–8) 4 (1–7) 0.535
Number  of vomiting episode per daya 5.5 (3–8) 3.5 (0–8) 0.214
Duration of vomiting, daysa 3 (1–10) 2.5 (0–6) 0.598
Feverb (≥37.5 ◦C) 4 (50%) 5 (50%) 1.0
Length  of hospital stay, daysa 6.5 (4–11) 4 (1–6) 0.006
Leukocytosisb (>104/mm3) 3 (30%) 4 (33%) 0.861
Viral loadc (GC/g) 3.9 × 1011 (2.6 × 1010–1.1 × 1012) 1.1 × 1011 (9.7 × 105–4.3 × 1011) 0.047
NoVs, noroviruses; AGE, acute gastroenteritis; GC/g, genome copies per gram.
a Median value (range).
b No. (%) of patients.
c Mean value (range).
d The duration of diarrhea was established from the onset of clinical symptoms up to the interview with parents/legal guardians, in general during the ﬁrst day of admission
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e Children with double infection of NoVs and group A rotavirus (n = 6) are not sho
. Discussion
The detection of RVA RNA and antigenemia among children with
GE is well established and documented [24–29]. However, few
tudies have investigated the presence of NoVs in serum samples
f children with NoVs-positive AGE [12,16,17]. In the present study
e found NoVs GII in 34.1% of the stool samples collected from
hildren admitted to hospital with AGE. Among the positive sam-
les, NoVs RNA was detected in the serum of a high proportion of
he cases (43%), excluding six samples that were co-infected with
VA. Our results showed that AGE in the group that presented NoVs
NA detection in serum was not more severe in terms of frequency
nd length of diarrhea and vomiting, fever, and leukocytosis. How-
ver, we found a statistically signiﬁcant difference in the duration
f hospitalization (p = 0.006) and stool viral load (p = 0.047) when
omparing the group of patients with and without NoVs RNA detec-
ion in serum.
We detected a high rate of NoVs viremia in patients with
orovirus excretion, as compared to range of positivity rates (15%
nd 25%) found in previous studies [16,17]. There is a theoretical
ossibility that screening of the stool samples using an EIA selects
or patients with a potentially high viral load, and therefore, the
iremia rate (34.5%) might be overestimated. Takanashi et al. [16]
lso found a high NoVs’ load in stool samples of serum-positive
ig. 1. Noroviruses (NoVs) GII viral load among the positive stool samples with and
ithout NoVs RNA in blood (p = 0.0472), and serum samples, represented by qRT-
CR  cycle number at which the ﬂuorescence meet the threshold in the ampliﬁcation
lot (Ct). Children with double infection of NoVs and group A rotavirus (n = 6) are
ot  shown.group, however with no statistically signiﬁcant difference. In addi-
tion, Ramani et al. [29] showed a statistically signiﬁcant correlation
between the presence and levels of RVA antigen in serum samples
and stool viral load.
Our results suggest that a high replication and resulting viral
load could cause greater injure to the epithelium, leading NoVs to
reach the intestinal lamina propria, and consequently blood vessels.
A similar mechanism, concerning the RVA entry in blood stream,
was also proposed by Ramani et al. [29]
Phylogenetic analysis of NoVs strains showed the high circu-
lation of genotype GII.4 (90%) among the sequenced strains. This
genotype was the most prevalent, as described in several studies
in Brazil and elsewhere. Sub-typing of GII.4 demonstrated that all
strains belonged to variant 2010. This GII.4 variant 2010 (also called
New Orleans) was ﬁrst detected in October 2009 in United States,
and was  responsible for 60% of the outbreaks during the 2009–2010
season [30]. This variant was also detected in several countries
of Europe [31], conﬁrming the global spread of this new vari-
ant; an evolution pattern previously demonstrated for others GII.4
variants. Two strains detected in stool samples without viremia
were classiﬁed as GII.7. This genotype was  previously detected
in others Brazilian’s states in 2005 [32,33]. The two NoVs strains
sequenced from sera matched 100%, at nt level, with their respec-
tive sequences obtained from faecal samples, corroborating results
previously found. [12,16] The presence of the same strain in both
samples reinforces the intestinal route as the entry site for NoVs to
achieve the blood stream, as also suggested by Medici et al. [12].
An evaluation of a true viremia for NoVs (infectious viruses
circulating in the blood stream) is hampered since no fully per-
missive cell system has been established for this agent to date.
The present study describes preliminary results concerning NoVs
from children hospitalized for AGE and is part of a major ongoing
surveillance investigation with the primary objective of assessing
RVA viremia. An additional limitation is that we did not search for
enteropathogens other than rotavirus, for instance, bacteria, that
might have a role in clinical severity.
Unlike RVA, few studies associate NoVs with extra-intestinal
spread. We  found here that NoV GII is not uncommonly dis-
seminated to blood stream, since 34.5% (10/29) of children with
NoV-positive AGE presented detectable viral level in serum sam-
ples. Our data suggest that the presence of RNA in serum correlates
with a longer duration of hospital stay, as well as with a higher
stool viral load. These results also suggest that NoVs GII could
spread beyond the intestine and into the bloodstream. Our ﬁnd-
ings could help explain the relationship between severe AGE and
viremia, and a possible link with systemic symptoms. This is the
ﬁrst study conducted in Brazil concerning the detection of NoV in
34 T.M. Fumian et al. / Journal of Clinic
Fig. 2. Phylogenetic dendrogram based on partial capsid nucleotide sequences of
noroviruses (NoVs) GII strains detected from stool (n = 14) and serum samples (n = 2)
of  hospitalized children with acute gastroenteritis. NoV prototypes were obtained
from GenBank, and genotypes and their respective accession numbers are indicated
at  the right. Fecal (F) and serum (S) samples are marked with a ﬁlled and an unﬁlled
diamond, respectively. The scale bar at the bottom of the tree indicates distance.
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oVs pathogenesis.
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